CY1113519T1 - Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης - Google Patents

Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης

Info

Publication number
CY1113519T1
CY1113519T1 CY20121100415T CY121100415T CY1113519T1 CY 1113519 T1 CY1113519 T1 CY 1113519T1 CY 20121100415 T CY20121100415 T CY 20121100415T CY 121100415 T CY121100415 T CY 121100415T CY 1113519 T1 CY1113519 T1 CY 1113519T1
Authority
CY
Cyprus
Prior art keywords
group
hydroxy
venzazepin
vasopresine
components
Prior art date
Application number
CY20121100415T
Other languages
Greek (el)
English (en)
Inventor
Kazumi Kondo
Yasuhiro Menjo
Takahiro Tomoyasu
Shin Miyamura
Yuso Tomohira
Takakuni Matsuda
Keigo Yamada
Yusuke Kato
Original Assignee
Otsuka Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd filed Critical Otsuka Pharmaceutical Co., Ltd
Publication of CY1113519T1 publication Critical patent/CY1113519T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/5532—Seven-(or more) membered rings
    • C07F9/5535—Seven-(or more) membered rings condensed with carbocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20121100415T 2007-06-26 2012-05-04 Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης CY1113519T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007167207 2007-06-26
EP08765871A EP2170831B1 (en) 2007-06-26 2008-06-26 Benzazepine derivatives useful as vasopressin antagonists

Publications (1)

Publication Number Publication Date
CY1113519T1 true CY1113519T1 (el) 2016-06-22

Family

ID=39773045

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20121100415T CY1113519T1 (el) 2007-06-26 2012-05-04 Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης
CY20131100894T CY1114491T1 (el) 2007-06-26 2013-10-10 Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης
CY20141100426T CY1115226T1 (el) 2007-06-26 2014-06-11 Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20131100894T CY1114491T1 (el) 2007-06-26 2013-10-10 Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης
CY20141100426T CY1115226T1 (el) 2007-06-26 2014-06-11 Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης

Country Status (27)

Country Link
US (3) US8669229B2 (OSRAM)
EP (3) EP2170831B1 (OSRAM)
JP (3) JP5653043B2 (OSRAM)
KR (1) KR101487201B1 (OSRAM)
CN (3) CN103342679A (OSRAM)
AR (1) AR067176A1 (OSRAM)
AT (1) ATE545633T1 (OSRAM)
AU (1) AU2008269918B2 (OSRAM)
BR (1) BRPI0813768A2 (OSRAM)
CA (1) CA2690335A1 (OSRAM)
CO (1) CO6160295A2 (OSRAM)
CY (3) CY1113519T1 (OSRAM)
DK (3) DK2170831T3 (OSRAM)
ES (3) ES2380085T3 (OSRAM)
HR (3) HRP20120310T1 (OSRAM)
IL (1) IL202561A0 (OSRAM)
MY (3) MY148312A (OSRAM)
NZ (3) NZ581723A (OSRAM)
PH (2) PH12012501363A1 (OSRAM)
PL (3) PL2170831T3 (OSRAM)
PT (3) PT2170831E (OSRAM)
RU (1) RU2471784C2 (OSRAM)
SG (2) SG182230A1 (OSRAM)
SI (3) SI2374797T1 (OSRAM)
TW (1) TWI459947B (OSRAM)
UA (1) UA98966C2 (OSRAM)
WO (1) WO2009001968A1 (OSRAM)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑
JP5656399B2 (ja) * 2008-12-26 2015-01-21 大塚製薬株式会社 医薬及び医薬製剤
CN102030709B (zh) * 2009-09-25 2013-10-16 江苏豪森医药集团有限公司 用作加压素受体拮抗剂的苯并氮杂卓类化合物
EA022253B1 (ru) * 2009-10-26 2015-11-30 Оцука Фармасьютикал Ко., Лтд. Соединение бензазепина и его применения
GB201105537D0 (en) 2011-03-31 2011-05-18 Vantia Ltd New process
CN102260213B (zh) * 2011-05-31 2013-05-15 重庆福安药业(集团)股份有限公司 一种托伐普坦的制备方法
TWI704919B (zh) * 2012-05-31 2020-09-21 日商大塚製藥股份有限公司 用於預防及/或治療多囊性腎臟病之藥物
CA2894516A1 (en) 2012-12-28 2014-07-03 Otsuka Pharmaceutical Co., Ltd. Injectable depot formulation comprising optically active tolvaptan and process of producing the same
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
TWI660748B (zh) * 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液
TW201605488A (zh) 2013-10-15 2016-02-16 大塚製藥股份有限公司 用以預防及／或治療多囊腎病之藥物
US11911369B2 (en) * 2015-03-03 2024-02-27 Biohaven Therapeutics Ltd. Prodrugs of riluzole and their method of use
WO2019003433A1 (ja) * 2017-06-30 2019-01-03 大塚製薬株式会社 ベンゾアゼピン誘導体
CN107540672A (zh) * 2017-10-10 2018-01-05 牡丹江医学院 一种治疗肝硬化的药物及其合成方法
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物
JP2020011957A (ja) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド トレプロスチニル誘導体化合物およびその使用方法
CN112851583B (zh) * 2021-01-19 2023-09-08 徐州医科大学 新型苯并氮杂䓬类化合物、组合物及其用途
TW202246216A (zh) 2021-02-10 2022-12-01 大陸商上海森輝醫藥有限公司 苯并氮雜環庚烯類化合物及其製備方法和醫藥用途
CN113112528A (zh) * 2021-04-26 2021-07-13 中南财经政法大学 异常行为监控方法、装置、设备及存储介质

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5045478A (en) * 1986-03-03 1991-09-03 Becton Dickinson And Company Vesicles and use thereof in an assay
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
CA2116334A1 (en) 1992-07-02 1994-01-20 Hidenori Ogawa Oxytocin antagonist
TW270927B (OSRAM) * 1992-10-16 1996-02-21 Otsuka Pharma Co Ltd
GB9726695D0 (en) 1997-12-17 1998-02-18 Smithkline Beecham Plc Novel compounds
JP4210355B2 (ja) 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
CN1165532C (zh) 1998-09-29 2004-09-08 惠氏控股有限公司 作为蛋白质酪氨酸激酶抑制剂的取代的3-氰基喹啉
US6642270B2 (en) * 2000-05-15 2003-11-04 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
CN101374539A (zh) * 2004-11-02 2009-02-25 夏尔有限责任公司 改善肝脏递送的利巴韦林前药
ES2533007T3 (es) * 2005-12-27 2015-04-06 Otsuka Pharmaceutical Co., Ltd. Compuesto de benzoacepina soluble en agua y su composición farmacéutica
TWI459947B (zh) * 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑

Also Published As

Publication number Publication date
HRP20131095T1 (hr) 2014-01-03
HRP20120310T1 (hr) 2012-06-30
JP2010531293A (ja) 2010-09-24
PT2374797E (pt) 2014-05-02
AR067176A1 (es) 2009-09-30
HK1163660A1 (en) 2012-09-14
WO2009001968A1 (en) 2008-12-31
MY152805A (en) 2014-11-28
EP2374798A1 (en) 2011-10-12
US20140024640A1 (en) 2014-01-23
DK2170831T3 (da) 2012-05-21
CA2690335A1 (en) 2008-12-31
JP5653043B2 (ja) 2015-01-14
EP2374797B1 (en) 2014-03-26
HK1141994A1 (en) 2010-11-26
BRPI0813768A2 (pt) 2014-12-30
JP5689195B2 (ja) 2015-03-25
PL2374798T3 (pl) 2014-01-31
SG182231A1 (en) 2012-07-30
EP2170831B1 (en) 2012-02-15
NZ581723A (en) 2012-03-30
IL202561A0 (en) 2010-06-30
US20140024619A1 (en) 2014-01-23
JP5893085B2 (ja) 2016-03-23
DK2374797T3 (da) 2014-05-12
PT2170831E (pt) 2012-04-13
EP2374797A1 (en) 2011-10-12
SI2374797T1 (sl) 2014-05-30
JP2014208680A (ja) 2014-11-06
EP2374798B1 (en) 2013-09-04
NZ598067A (en) 2012-12-21
ES2431515T3 (es) 2013-11-26
TW200911271A (en) 2009-03-16
ES2460018T3 (es) 2014-05-13
NZ598064A (en) 2013-04-26
SG182230A1 (en) 2012-07-30
DK2374798T3 (da) 2013-10-07
AU2008269918B2 (en) 2012-12-06
KR101487201B1 (ko) 2015-01-28
CN103342680A (zh) 2013-10-09
US8785386B2 (en) 2014-07-22
ATE545633T1 (de) 2012-03-15
ES2380085T3 (es) 2012-05-08
CY1114491T1 (el) 2016-10-05
PT2374798E (pt) 2013-11-05
PL2374797T3 (pl) 2014-08-29
CO6160295A2 (es) 2010-05-20
TWI459947B (zh) 2014-11-11
PH12012501362A1 (en) 2014-04-28
HK1163077A1 (en) 2012-09-07
UA98966C2 (ru) 2012-07-10
CN101687805A (zh) 2010-03-31
EP2170831A1 (en) 2010-04-07
US20110071084A1 (en) 2011-03-24
RU2471784C2 (ru) 2013-01-10
SI2374798T1 (sl) 2013-10-30
MY148312A (en) 2013-03-29
RU2010102229A (ru) 2011-08-10
AU2008269918A1 (en) 2008-12-31
MY150941A (en) 2014-03-14
KR20100040873A (ko) 2010-04-21
US9073868B2 (en) 2015-07-07
CN103342679A (zh) 2013-10-09
CY1115226T1 (el) 2017-01-04
JP2014205703A (ja) 2014-10-30
PL2170831T3 (pl) 2012-08-31
SI2170831T1 (sl) 2012-04-30
PH12012501363A1 (en) 2014-04-28
US8669229B2 (en) 2014-03-11
HRP20140501T1 (hr) 2014-07-04

Similar Documents

Publication Publication Date Title
CY1114491T1 (el) Παραγωγα βενζαζεπινης χρησιμα ως ανταγωνιστες της βαζοπρεσινης
EA201070988A1 (ru) Противовирусные терапевтические средства
MX342683B (es) Analogos de ciclopamina.
PE20090730A1 (es) Derivados de piridina como moduladores de los canales de sodio
CY1118048T1 (el) Αντι-ιικες ενωσεις
CY1118196T1 (el) Νεα κρυσταλλικη μορφη vi της αγομελατινης, μεθοδος παρασκευης αυτης και οι φαρμακευτικες συνθεσεις που την περιεχουν
CY1117482T1 (el) Παραγωγα πλευρομουτιλινης για τη θεραπεια ασθενειων που προκαλουνται απο μικροβια
CY1115738T1 (el) Κρυσταλλικα επιδιαλυτωμενα συμπλοκα των παραγωγων (1s)-1,5-anyδpo-1-c-(3-((φainyλ)meθυλ) φαινυλ)-d-γλουσιτολης με αλκοολες οπως αναστολεις sglt2 για τη θεραπευτικη αντιμετωπιση του διαβητη
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
CY1113812T1 (el) Ετεροκυκλικη ενωση και φαρμακευτικη συνθεση αυτης
CY1115809T1 (el) Φουραζανοβενζιμιδαζολες ως προφαρμακα για τη θεραπεια νεοπλασματικων ή αυτοανοσων ασθενειων
CR20110268A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
PH12012502284A1 (en) Antiviral nucleoside analogs
UY33205A (es) Naftiridinas sustituidas y su uso como medicamentos
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
EA201000101A1 (ru) Производные пиримидина 934
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
CY1117560T1 (el) Νεο υποκατασταθεν παραγωγο ισοκινολινης
EA200801054A1 (ru) Производные пролинамида в качестве модуляторов натриевых каналов
EA201001087A1 (ru) Новые дигидроиндолоновые соединения, способ их получения и фармацевтические композиции, содержащие их
CY1112877T1 (el) Μεταλλαγματα αυξητικου παραγoντα υψηλης δραστικοτητας
BR112012009861A2 (pt) composto, composição farmacêutica, e, uso do composto.
CY1116596T1 (el) Αλατα ισοφωσφοραμιδικης μουσταρδας και αναλογα αυτων
CU24719B1 (es) Derivados de hidroquinona disustituidos en 2,5 o 2,6 con un grupo carboxi, sulfo o amido útiles como medicamentos
RU2014124531A (ru) (1r,4r) 7-оксо-2-азабицикло[2.2.2]окт-5-ен и его производные